Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (NCT03814746)
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.
Who can join: Review the eligibility criteria below.
Location: Childrens Healthcare of Atlanta — Atlanta, Georgia
Age range: 12 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (58 Sites)
Showing the first 25 of 58 sites.
- Childrens Healthcare of Atlanta — Atlanta, Georgia
- Boston Medical Center — Boston, Massachusetts
- Levine Cancer Insitute Carolinas Healthcare System — Charlotte, North Carolina
- Univ of Tenn Health Sciences Ctr — Memphis, Tennessee
- U of TX Health Science Ct — Houston, Texas
- Novartis Investigative Site — Brussels, Brussels Capital
- Novartis Investigative Site — Brussels,
- Novartis Investigative Site — Edegem,
- Novartis Investigative Site — Salvador, Estado de Bahia
- Novartis Investigative Site — Belém, Pará
- Novartis Investigative Site — Recife, Pernambuco
- Novartis Investigative Site — Rio de Janeiro, Rio de Janeiro
- Novartis Investigative Site — Porto Alegre, Rio Grande do Sul
- Novartis Investigative Site — Ribeirão Preto, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Barranquilla, Atlántico
- Novartis Investigative Site — Valledupar, Cesar Department
- Novartis Investigative Site — Montería,
- Novartis Investigative Site — Helsinki,
- Novartis Investigative Site — Créteil,
- Novartis Investigative Site — Marseille,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease (SCD)
- Megakaryocyte Heterogeneity in Sickle Cell Disease — Pointe-à-Pitre,
- Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Birmingham, Alabama
- Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia — Montreal, Quebec
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Atlanta, Georgia
Explore by condition: All Sickle Cell Disease (SCD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.